General Information of Drug (ID: DMABKHH)

Drug Name
ARO-APOC3
Indication
Disease Entry ICD 11 Status REF
Familial chylomicronemia syndrome 5C80 Phase 3 [1]
Hypertriglyceridemia 5C80.1 Phase 2 [2]
Drug Type
RNA interference
Cross-matching ID
TTD ID
DNF8Z1

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ApoC-III messenger RNA (APOC3 mRNA) TTXOZQ1 APOC3_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Familial chylomicronemia syndrome
ICD Disease Classification 5C80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
ApoC-III messenger RNA (APOC3 mRNA) DTT APOC3 2.67E-01 0.1 0.59
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05089084) A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04720534) A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia. U.S.National Institutes of Health.
3 ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.